{"Clinical Trial ID": "NCT00696072", "Intervention": ["INTERVENTION 1:", "Dasatinib Plus Letrozole", "Dasatinib + Letrozole: Tablets, Oral, once daily, up to 2 years", "Dasatinib 100 mg + Letrozole 2.5 mg", "If the intolerable toxicity was determined to be related to dasatinib, dasatinib was discontinued and the patient continued to take mono-agent letrozole. Although the drugs were taken daily, the cycle duration was 28 days.", "INTERVENTION 2:", "- Letrozole", "Letrozole: Oral tablets, 2.5 mg, once daily, up to 2 years", "While the drugs were taken daily, the cycle duration was 28 days."], "Eligibility": ["For more information on participation in BMS clinical trials, please visit www.BMSStudyConnect.com.", "Incorporation criteria:", "\u00b7 Has a histological or cytological diagnosis of breast cancer; evidence of locally recurrent or metastatic non-resectable disease", "A measurable or evaluable disease only", "Is female, 18 years old, postmenopausal menopause or surgically sterile", "- negative HER2, HR+, ER+ and/or PgR+ breast cancer", "0-1 prior treatment of chemotherapy for metastatic disease.", "Previous adjuvant or neoadjuvant chemotherapy completed at least one month before", "Prior treatment with tamoxifen is permitted.", "No AI treatment for > 1 year without recurrence", "- Exclusion criteria:", "Maternal or maternal breast-feeding", "Pre-hormonal treatment for metastatic or locally recurrent diseases", ">1 chemotherapy regimen for metastatic diseases", "Pleural or pericardial effusion", "Serious heart disease"], "Results": ["Performance measures:", "Number of participants with a clinical benefit (CFR) and number of participants with a disease-free interval (DFI) of more than 2 years - avoidable population", "RRC=participants with a complete response (RC) + participants with a partial response (PR) + participants with a stable disease (SD) for a duration greater than, equal to 6 months RRC= Disappearance of all target lesions No new lesions RP= At least 30% of the sum of the longest diameter (LD) of the target lesions taking as a reference the base sum of the LD. RRC= Neither a narrowing sufficient to qualify for RP nor an increase sufficient to qualify for progressive disease (PD) taking as a reference the smallest sum of LD since the start of treatment Physical examination, radiological evaluation and bone scans (if any) were used to assess the outcome.", "Delay: First dose of the medicine at the last dose plus 7 days, until the end of the study (approximately 6 years)", "Results 1:", "Title of the arm/group: Dasatinib Plus Letrozole", "Description of the arm/group: Dasatinib + Letrozole: Tablets, Oral, once daily, up to 2 years", "Dasatinib 100 mg + Letrozole 2.5 mg", "If the intolerable toxicity was determined to be related to dasatinib, dasatinib was discontinued and the patient continued to take mono-agent letrozole. Although the drugs were taken daily, the cycle duration was 28 days.", "Total number of participants analysed: 56", "Type of measurement: Number", "Unit of measurement: participants CBR (CR+PR+SD): 40", "CBR, DFI <= 2 years: 20", "CBR, DFI > 2 years: 20", "Results 2:", "Title of the arm/group: Letrozole", "Description of the arm/group: Letrozole: Oral tablets, 2.5 mg, once daily, up to 2 years", "While the drugs were taken daily, the cycle duration was 28 days.", "Total number of participants analysed: 61", "Type of measurement: Number", "Unit of measurement: participants CBR (CR+PR+SD): 40", "CBR, DFI <= 2 years: 20", "CBR, DFI > 2 years: 20"], "Adverse Events": ["Undesirable Events 1:", "Total: 14/57 (24.56 per cent)", "Anemia * 0/57 (0.00 %)", "CVA * 2/57 (3.51%)", "Heart failure * 0/57 (0.00 %)", "Congestive heart failure * 0/57 (0.00 %)", "Coronary heart failure * 1/57 (1.75%)", "Pericardial infusion * 0/57 (0.00 %)", "Cholelithiasis * 1/57 (1.75%)", "- Collision * 0/57 (0.00 %)", "Dehydration * 1/57 (1.75%)", "Diverticulitis * 0/57 (0.00 %)", "Nausea * 2/57 (3.51%)", "Adverse Events 2:", "Total: 2/63 (3.17 per cent)", "Anemia * 1/63 (1.59%)", "CVA * 0/63 (0.00 %)", "* 1/63 (1.59%)", "Congestive heart failure * 1/63 (1.59%)", "Coronary heart failure * 0/63 (0.00 %)", "* 1/63 (1.59%)", "Cholelithiasis * 0/63 (0.00 %)", "* 1/63 (1.59%)", "Dehydration * 1/63 (1.59%)", "Diverticulitis * 1/63 (1.59%)", "Nausea * 0/63 (0.00 %)"]}